CVSS3
Attack Vector
LOCAL
Attack Complexity
LOW
Privileges Required
LOW
User Interaction
NONE
Scope
UNCHANGED
Confidentiality Impact
HIGH
Integrity Impact
HIGH
Availability Impact
LOW
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L
EPSS
Percentile
9.0%
--------- Begin Update A part 1 of 2 ---------
--------- End Update A part 1 of 2 ---------
This updated advisory is a follow-up to the original advisory titled ICSMA-23-047-01 BD Alaris Infusion Central that was published February 16, 2023, to the ICS webpage on www.cisa.gov/uscert.
Successful exploitation of this vulnerability could allow an attacker to obtain the database installation password and gain access to the Alaris Infusion Central database, resulting in disclosure of resident personal data.
The following BD software products are affected:
--------- Begin Update A part 2 of 2 ---------
4.2.1 STORING PASSWORDS IN A RECOVERABLE FORMAT CWE-257
--------- End Update A part 2 of 2 ---------
Alaris Infusion Central versions 1.1–1.3.2 may contain a recoverable password after installation, which could allow an attacker to disclose or tamper with resident personal data. Patient health data is not stored in the database, although some side installations may choose to store personal data.
CVE-2022-47376 has been assigned to this vulnerability. A CVSS v3 base score of 7.3 has been assigned; the CVSS vector string is (AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L).
BD reported this vulnerability to CISA.
BD is directly reaching out to the small group of customers who may be impacted by this vulnerability to initiate remediation.
BD recommends the following mitigations and compensating controls to reduce risk associated with this vulnerability:
For additional information, refer to BD’s security bulletin.
CISA reminds organizations to perform proper impact analysis and risk assessment prior to deploying defensive measures.
CISA also provides a section for control systems security recommended practices on the ICS webpage at cisa.gov/ics. Several CISA products detailing cyber defense best practices are available for reading and download, including Improving Industrial Control Systems Cybersecurity with Defense-in-Depth Strategies.
Additional mitigation guidance and recommended practices are publicly available on the ICS webpage at cisa.gov/ics in the technical information paper, ICS-TIP-12-146-01B–Targeted Cyber Intrusion Detection and Mitigation Strategies.
Organizations observing suspected malicious activity should follow established internal procedures and report findings to CISA for tracking and correlation against other incidents.
CISA also recommends users take the following measures to protect themselves from social engineering attacks:
No known public exploits specifically target this vulnerability. This vulnerability is not exploitable remotely.
web.nvd.nist.gov/view/vuln/detail?vulnId=CVE-2022-47376
cisa.gov/ics
cisa.gov/ics
cisasurvey.gov1.qualtrics.com/jfe/form/SV_9n4TtB8uttUPaM6?product=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01
cwe.mitre.org/data/definitions/257.html
public.govdelivery.com/accounts/USDHSCISA/subscriber/new?topic_id=USDHSCISA_138
twitter.com/CISAgov
twitter.com/intent/tweet?text=BD%20Alaris%20Infusion%20Central%20%28Update%20A%29+https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01
us-cert.cisa.gov/ics/Recommended-Practices
us-cert.cisa.gov/sites/default/files/recommended_practices/NCCIC_ICS-CERT_Defense_in_Depth_2016_S508C.pdf
www.bd.com/en-us/about-bd/cybersecurity/bulletin/alaris-infusion-central-recoverable-password-vulnerability
www.cisa.gov/uscert/ics/tips/ICS-TIP-12-146-01B
www.cisa.gov/uscert/ncas/tips/ST04-014
www.cisa.gov/uscert/sites/default/files/publications/emailscams_0905.pdf
www.dhs.gov
www.dhs.gov/foia
www.dhs.gov/performance-financial-reports
www.facebook.com/CISA
www.facebook.com/sharer/sharer.php?u=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01&title=BD%20Alaris%20Infusion%20Central%20%28Update%20A%29
www.first.org/cvss/calculator/3.0#CVSS:3.0/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:L
www.instagram.com/cisagov
www.linkedin.com/company/cybersecurity-and-infrastructure-security-agency
www.linkedin.com/sharing/share-offsite/?url=https://www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01
www.oig.dhs.gov/
www.usa.gov/
www.whitehouse.gov/
www.youtube.com/@cisagov
mailto:?subject=BD%20Alaris%20Infusion%20Central%20%28Update%20A%29&body=www.cisa.gov/news-events/ics-medical-advisories/icsma-23-047-01